Scientists at Helmholtz Munich identify ACSL4 enzyme as crucial for ferroptosis, a form of cell death linked to cancer and neurodegenerative diseases. The researchers found that ACSL4 plays a central role in generating the signal that initiates cell death, providing new insights into the development of potential therapeutic approaches.
A new mechanism regulating glucose metabolism has been discovered by researchers at Helmholtz Munich. The transforming growth factor beta 1-stimulated clone 22 D4 (TSC22D4) gene acts as a molecular switch in the liver, influencing genes that can regulate metabolism throughout the body.
Researchers at Helmholtz Munich have discovered proteins in the blood that can predict incipient type 1 diabetes, even before symptoms appear. The study identified 41 peptides from 26 proteins that distinguish children with autoantibodies from those without, including proteins associated with lipid metabolism.
Scientists at Helmholtz Zentrum München have discovered a mechanism used by the immune system to prepare for attacks on insulin-producing cells in the pancreas. The team identified a signaling pathway triggered by miRNA92a, which leads to an increase in immune cells that promote autoimmunity. Targeted intervention using antagomirs may ...
Scientists at Helmholtz Zentrum München discovered a mechanism by which EBV virus suppresses alarm signals sent out by infected cells. MicroRNAs made by the virus block production of proteins that would ring the alarm, rendering killer T cells and helper T cells inactive.
Exposure to air pollution at home increases the risk of developing insulin resistance, a pre-diabetic state of type 2 diabetes. The study analyzed data from nearly 3,000 participants and found that people with impaired glucose metabolism are particularly vulnerable to the effects of air pollution.
A study by Helmholtz Zentrum München found that myeloid-derived suppressor cells (MDSC) are increased in the blood of patients with idiopathic pulmonary fibrosis (IPF), correlating with lung function decline. MDSC may serve as a biomarker for IPF diagnosis and disease progression.
Researchers developed an algorithm to analyze single-cell sequencing data, revealing the genetic control of blood cell formation. The 'diffusion pseudotime' method orders cells on a virtual timeline, reconstructing developmental paths and gene expression sequences.
Researchers have identified AMPK as the central enzyme in cancer cachexia, a condition that results in weight loss due to metabolic complications. A peptide was developed to selectively reactivate AMPK, which has been shown to prevent increased fat breakdown and promote 'healthy' adipose tissue.
Researchers found that an extract from house dust mites triggers different responses depending on the age of the person, with leukotrienes playing a key role in adults. The study suggests that cortisone therapy may not be effective against this type of allergy and that targeted therapies could be more effective.
Researchers at Helmholtz Zentrum München have developed a new test to diagnose the specific venom causing an allergic reaction, enabling the creation of personalized vaccines. This breakthrough has the potential to improve treatment options for patients with allergies to wasp stings.
A recent study found that breastfeeding for over three months postpartum alters maternal metabolism, producing lower concentrations of branched-chain amino acids and phospholipids. This change in metabolites is linked to reduced insulin resistance and a lower risk of developing type 2 diabetes.
A new software has been developed to analyze time-lapse microscopy movies, enabling the measurement of cellular properties such as cell cycle length and protein expression dynamics. The tool is freely available online and has already led to high-impact publications in top scientific journals.
A recent study reveals that ship engine emissions adversely affect macrophages, a key component of the immune system. The toxic effects of these emissions on macrophages can lead to pro-inflammatory reactions and other biological processes, highlighting the need for efficient particle-reducing measures.
A team of scientists at Helmholtz Munich developed a protocol to analyze metabolite composition in fixed tissues using mass spectrometry imaging. This method allows for the study of spatial distribution of molecules with high precision, enabling the identification of new predictive, diagnostic and prognostic markers.
Researchers discovered that a signaling molecule called TGF-beta inhibits genes important for glucose and fat burning, reducing insulin sensitivity. The study suggests that a tailored training program could help prevent type 2 diabetes by overcoming this molecular response.
Researchers at Helmholtz Munich discovered a new marker, Flattop, that subdivides insulin-producing beta cells into mature and immature subgroups. The study suggests that the Flattop-negative cells are a reserve pool for replenishing mature beta cells.
Scientists at Helmholtz Zentrum München have developed a novel antibody targeting carbonic anhydrase XII, which is overexpressed in cancer cells, with the goal of improving treatment options for glioblastoma patients. The antibody conjugated with lutetium-177 can deliver lethal doses to tumor cells directly.
Researchers have identified a small peptide from a bacterium that efficiently binds excess copper from liver cells, offering a potential treatment for Wilson disease. The molecule, methanobactin, was shown to reverse acute stages of the disease and prevent organ failure.
Researchers at Helmholtz Munich have developed a new method to predict disease progression in glioblastoma patients. By analyzing four specific miRNAs, they can identify patients who are at high risk of poor treatment outcomes and may benefit from alternative or intensified treatments.
Scientists at Helmholtz Zentrum München are developing new tests to assess risks posed by nanomaterials in the airways, aiming to reduce complex toxicity tests. The project uses modern methods like systems biology and computer modeling to predict nanotoxicity.
The Fr1da study has detected an early stage of type 1 diabetes in 105 out of 26,760 children aged two to five years. The children have not shown signs of metabolic imbalance, suggesting a potential breakthrough in preventive healthcare. Families are being offered comprehensive support and care.
Scientists at Helmholtz Munich discovered that fasting induces the production of a protein called GADD45β, which reduces fatty acid absorption in the liver and improves sugar metabolism. This finding holds promise for therapeutic intervention in metabolic diseases like type 2 diabetes.
A study by Helmholtz Munich researchers found that viral respiratory tract disorders during the first six months of life significantly increase the risk of children developing type 1 diabetes. The infection localization and timing were key factors in determining the increased risk.
Breast cancer cells challenged with a small-molecule inhibitor targeting specific invasive properties switch to an alternative mode-of-action, rendering them even more aggressive. The results suggest that inhibiting one pathway may not block all aggressiveness in breast cancer cells.
Researchers at Helmholtz Zentrum München have identified two variants of the protein MALT1, which are regulated by posttranscriptional splicing and affect the immune response. The study found that stronger activation of T cells is associated with the MALT1A variant, while the MALT1B variant results in a weaker response.
The immunoproteasome regulates alternative macrophage activation by inhibiting IL-4 signaling, reducing repair and clean-up functions. Targeted treatment with specific inhibitors may accelerate healing processes in the lung after acute pneumonia.
Scientists have developed novel insulin mimetopes that can induce regulatory T cells to produce tolerance against insulin, halting the development of type 1 diabetes in young mice. In a humanized mouse model, the new vaccine efficiently stimulates regulatory T cells, which can impede the immune system's attack on insulin-producing cells.
A recent study published in Nature Genetics found that mice offspring inherited epigenetic information from their parents' diets, leading to severe obesity. The research suggests that this epigenetic inheritance could be a major cause of the global increase in diabetes prevalence since the 1960s.
Researchers at Helmholtz Munich identified a new component regulating body weight and food intake, with histone deacetylase 5 (HDAC5) playing a significant influence on leptin's effect. The study found that HDAC5 is essential for the brain to recognize fat depot levels, enabling adaptation to food intake and reducing obesity.
The Helmholtz Zentrum Munchen has been awarded 14 ERC grants, with three scientists receiving 6 million euros. Dr. Daniel Razansky is investigating non-invasive brain imaging methods, while Dr. Irmela Jeremias focuses on targeted tumor treatment and Dr. Mathias Heikenwaelder explores immune system interactions in liver disease.
Scientists at Helmholtz Zentrum München discover that Cistus incanus extracts prevent human immunodeficiency viruses from infecting cells and block Ebola- and Marburg viral envelope proteins. The study demonstrates broad antiviral activity of Ci extracts against various major human viral pathogens.
Researchers at Helmholtz Zentrum München developed a method to analyze protein modifications, including the phosphorylation of RNA polymerase II. This helps regulate gene expression by controlling enzyme activity at precise sites.
A study by Helmholtz Munich found that cigarette smoke damages the immunoproteasome, a protein complex responsible for degrading and presenting foreign proteins to the immune system. This impairment weakens the immune response in COPD patients, making them more prone to viral infections.
Scientists have developed a new method for classifying cells based on large population of cell images, allowing for high specificity and accuracy. The approach uses machine learning to analyze bright and darkfield images, opening up new perspectives for cell cycle analysis and potential applications in various contexts.
Researchers successfully promoted the repair of an injured neural circuit in zebrafish using a special form of inducible adenylyl cyclase that responds to blue light, increasing repair rates by up to 30%. This breakthrough has potential therapeutic implications for conditions like diabetes-related neuropathies.
A new strategy to determine monocyte subsets involved in diseases has been developed, which may improve the diagnosis of sarcoidosis. The analysis of an additional marker molecule called slan allows a more precise determination of monocyte subgroups.
Researchers at Helmholtz Munich developed a method to predict the probability of developing postpartum diabetes after childbirth, using BMI and genetic predisposition as key factors. The test showed that women with low-risk scores had an 11% risk of developing diabetes within five years.
A study by Helmholtz Munich found that lung cancer patients incur an average of €20,000 in costs over three years. Surgery proved to be the most cost-effective treatment option, while chemotherapy and radiation therapy were more expensive.
A study by Helmholtz Munich researchers identified a key role of the protein BMP7 in promoting cell division and migration in pheochromocytoma cells. Targeting this signaling pathway with specific substances may lead to an increase in apoptosis, providing a new approach for treatment.
Researchers found that B cells enhance the secretion of allergy-driving IgE antibodies when exposed to non-allergenic compounds like PPE1. This discovery reveals a new mechanism for pollen allergy and offers new starting points for therapy development.
Researchers at Helmholtz Zentrum München found that Metformin decreases LDL cholesterol levels in Type 2 diabetes patients by regulating genes and metabolites involved in the AMPK pathway. The study suggests a potential additional beneficial effect of Metformin on cardiovascular diseases.
Researchers found that electrochemical disinfection creates numerous 'disinfection by-products', which can have unknown environmental impacts. Alternative methods like filtration or adsorption are recommended to prevent the transfer of harmful organisms.
A major European mouse study has identified the roles of 320 genes in mice, shedding light on their functions and potential links to human diseases. The study, led by Helmholtz Munich, provides valuable insights into genetic variations that can be used to develop personalized medicine approaches.
Researchers at Helmholtz Munich have discovered that increased protein turnover by the 26S proteasome is responsible for the activation of myofibroblasts, leading to pulmonary fibrosis. Inhibiting the 26S proteasome can prevent differentiation of primary human lung fibroblasts into myofibroblasts.
A novel mass spectrometry technique has enabled scientists to quantify and profile dynamic changes in lung tissue composition during regeneration. The study reveals the importance of extracellular matrix proteins in activating stem cells, offering a new avenue for treating chronic lung diseases like pulmonary fibrosis.
Natural killer cells are impaired in the tumor microenvironment, but can be restored in normal conditions. Researchers identified two key factors blocking NK cell function: inflammatory cytokine IL-10 and down-regulated NKG2D ligands.
Researchers found that subcutaneous administration of multispecific antibodies improves tumor treatment by better tolerability and undiminished effectiveness. The study suggests that this method could lead to broader availability of tumor treatment for patients, potentially eliminating hospitalization.
Researchers tracked nanoparticles in animal models, finding they accumulate mainly in the liver, while shell molecules distribute throughout the body. This discovery sheds light on nanoparticle properties and medical applications.
Scientists have established a model for latent HIV infection of brain cells and identified various compounds that can affect latency. The study aims to develop new therapeutic approaches to silence the virus in brain cells, which could improve clinical care for HIV-1 patients.